RESEARCH PROFILE
GHK-Cu
Copper Binding Tripeptide • Skin & Tissue Remodeling Research
GHK-Cu is a naturally occurring copper-binding tripeptide found in human plasma and other biological fluids. Research has focused on skin remodeling, collagen and elastin biology, wound repair, antioxidant signaling, gene expression, and copper-dependent cellular processes.
Human evidence is strongest for topical skin applications, while systemic injectable research remains substantially less developed.
NOT FDA APPROVED AS AN INJECTABLE DRUG • HUMAN TOPICAL EVIDENCE • PRECLINICAL SYSTEMIC RESEARCH
GHK-Cu AT A GLANCE
Category
Copper-binding regenerative peptide
Full Name
Glycyl-L-histidyl-L-lysine copper
Peptide Structure
Tripeptide complexed with copper
Primary Research Focus
Skin remodeling • Collagen • Elastin • Wound repair • Gene expression
Human Evidence
Strongest for topical cosmetic applications
Injectable Evidence
Primarily preclinical and community-derived
Regulatory Status
Not FDA approved as an injectable drug
IMPORTANT DISTINCTION
GHK-Cu has two very different evidence contexts.
Topical GHK-Cu has been studied in human cosmetic research involving skin appearance, collagen density, skin thickness, fine lines, and related endpoints.
Injectable GHK-Cu does not have the same human evidence base.
Your Project profile identifies no published randomized human trial evaluating injectable GHK-Cu for cosmetic, hair, wound-healing, or systemic regenerative endpoints.
Topical evidence should therefore not be presented as proof of injectable efficacy.
WHAT IS GHK-Cu?
GHK-Cu is a naturally occurring complex formed when the tripeptide glycyl-L-histidyl-L-lysine, or GHK, binds copper.
It was originally identified in human plasma.
Your Project profile notes that circulating GHK levels are higher earlier in life and decline substantially with age.
GHK has a strong affinity for copper ions, producing the characteristic GHK-Cu complex.
Copper is an essential trace element involved in numerous biological processes, including enzymes associated with:
Collagen formation
Connective-tissue structure
Antioxidant defense
Energy metabolism
Pigmentation
Wound repair
GHK-Cu has therefore become a research target in skin biology, wound healing, tissue remodeling, gene expression, and regenerative signaling.
It is also commonly encountered in topical cosmetic products marketed as copper peptides.
However, topical cosmetic use and systemic injectable research represent substantially different exposure contexts and should be evaluated separately.
MECHANISM OF ACTION
GHK-Cu appears to influence multiple cellular pathways rather than acting through one single established receptor.
COPPER DELIVERY
GHK binds copper and can transport it into biological environments where copper-dependent enzymes require the mineral.
This may help support processes involving connective tissue, antioxidant enzymes, and cellular repair.
COLLAGEN & ELASTIN
One of the most studied effects of GHK-Cu is its influence on extracellular-matrix biology.
Research suggests GHK-Cu can stimulate dermal fibroblasts and influence production of:
Collagen
Elastin
Glycosaminoglycans
These molecules contribute to skin structure, elasticity, hydration, and connective-tissue integrity.
DECORIN
Your Project source also identifies increased decorin, a small proteoglycan involved in regulation and organization of collagen fibers.
MATRIX REMODELING
GHK-Cu has been reported to influence matrix metalloproteinases and their inhibitors.
These systems participate in breakdown and reconstruction of extracellular matrix.
This means GHK-Cu research concerns not simply making more collagen, but potentially influencing tissue remodeling and organization.
GENE EXPRESSION
GHK-Cu has also been studied for its effects on gene expression.
Research cited in the Project profile suggests that GHK may influence expression of thousands of human genes, including patterns associated with tissue repair, antioxidant activity, inflammation, and extracellular-matrix biology.
WOUND-REPAIR SIGNALING
Animal research has reported effects involving:
Wound contraction
Collagen deposition
Angiogenesis
Tissue remodeling
These findings contribute to interest in GHK-Cu as a regenerative peptide.
IMPORTANT MECHANISM LIMITATION
Mechanistic and gene-expression findings demonstrate biological activity.
They do not establish that injectable GHK-Cu produces clinically meaningful anti-aging, hair-growth, wound-healing, or systemic regenerative outcomes in humans.
WHAT THE RESEARCH SHOWS
TOPICAL HUMAN EVIDENCE
The strongest human evidence for GHK-Cu involves topical skin applications.
Your Project profile identifies a controlled facial-cream study involving 71 women who applied GHK-Cu cream for approximately 12 weeks.
Reported improvements included measures involving:
Skin density
Skin thickness
Fine lines
Skin laxity
The GHK-Cu formulation reportedly performed better than placebo and vitamin K cream on several measured endpoints.
RECENT HUMAN TOPICAL RESEARCH
Your Project source also cites a 2023 IRB-approved 21-woman pilot study involving a stabilized GHK-Cu topical gel.
After approximately three months, investigators reported an average 28% increase in skin collagen density, with the highest-response quartile reporting substantially larger increases.
This provides more recent human evidence for topical GHK-Cu.
The study was still relatively small and should be interpreted accordingly.
SKIN REMODELING
Human and laboratory research supports continued investigation of GHK-Cu in:
Collagen synthesis
Skin density
Fine-line appearance
Skin elasticity
Extracellular-matrix remodeling
This is the area where the evidence translates most directly to humans.
GENE-EXPRESSION RESEARCH
Your Project source cites research using the Broad Institute Connectivity Map to examine GHK-associated gene-expression patterns.
Researchers reported modulation of expression across thousands of human genes, including shifts toward patterns associated with younger or healthier tissue.
This is mechanistic evidence.
Gene-expression changes should not automatically be interpreted as demonstrated rejuvenation or clinical anti-aging.
PRECLINICAL WOUND HEALING
Animal wound-healing studies involving rats, mice, rabbits, and pigs have reported:
Faster wound contraction
Increased collagen
Improved angiogenesis
Improved healing in some injury models
These studies provide a biological rationale for regenerative research.
They are not equivalent to human clinical trials.
HAIR RESEARCH
GHK-Cu is frequently discussed in hair-growth contexts.
The Project profile identifies the evidence as considerably less established than the topical skin literature.
Mechanistic plausibility and cosmetic use should not be represented as proof that GHK-Cu treats human hair loss.
INJECTABLE GHK-Cu
This is the major evidence gap.
Your Project source identifies no published randomized human trial evaluating injectable GHK-Cu for cosmetic, hair, wound-healing, or systemic regenerative endpoints.
Community discussions of subcutaneous GHK-Cu therefore extend beyond the strongest clinical evidence.
IMPORTANT EVIDENCE LIMITATION
Evidence must remain separated by route:
Topical GHK-Cu: meaningful human cosmetic evidence
Injectable GHK-Cu: primarily preclinical and community-derived evidence
Strong topical evidence does not automatically transfer to systemic injection.
SAFETY & RESEARCH CONSIDERATIONS
GHK-Cu has a relatively long history of topical cosmetic use, but the safety profile differs substantially between topical and systemic exposure.
TOPICAL EFFECTS
Your Project profile identifies reported topical effects including:
Redness
Tingling
Dryness
Transient irritation
These effects are generally local.
Irritation may become more likely when GHK-Cu is combined with other aggressive topical products.
INJECTABLE EFFECTS
The injectable safety database is much weaker.
Community reports cited in the Project profile include:
Localized redness
Mild swelling
Transient warmth
Blue-tinted bruising related to the copper complex
These observations are anecdotal and should not be treated as a validated clinical adverse-event profile.
COPPER EXPOSURE
GHK-Cu contains biologically available copper.
Repeated high systemic exposure creates a theoretical concern for copper accumulation, particularly in individuals with impaired copper metabolism.
WILSON'S DISEASE & COPPER DISORDERS
Your Project profile specifically identifies Wilson's disease and other copper-handling disorders as important concerns.
Individuals with known copper-metabolism disorders should not assume GHK-Cu exposure is benign.
LIVER CONSIDERATIONS
Because the liver plays an important role in copper handling, significant liver disease is also relevant when considering repeated systemic copper exposure.
ANGIOGENESIS & CANCER
GHK-Cu has been associated with angiogenic and tissue-remodeling pathways.
Your Project profile therefore identifies active cancer or untreated solid tumors as situations requiring particular caution.
The clinical significance of this pathway in humans remains uncertain.
This does not establish that GHK-Cu causes cancer.
PREGNANCY & BREASTFEEDING
The Project source identifies insufficient evidence establishing safety during pregnancy or lactation.
PRODUCT QUALITY
Research-grade injectable products create additional risks unrelated to the peptide's intrinsic pharmacology.
Potential concerns include:
Incorrect concentration
Contamination
Sterility problems
Degradation
Mislabeling
Lot-to-lot variability
Lot-specific analytical testing can characterize a tested sample but does not establish medical safety.
REGULATORY CONTEXT
INJECTABLE GHK-Cu IS NOT FDA APPROVED
GHK-Cu is not an FDA-approved injectable drug.
No FDA-approved prescription injectable GHK-Cu product is identified in your Project source.
TOPICAL COSMETIC USE
Copper tripeptide-1 appears in cosmetic ingredient contexts and is used in topical skin-care products.
Cosmetic ingredient use is not equivalent to FDA approval as a therapeutic drug.
A cosmetic product containing a copper peptide should therefore not be represented as evidence that injectable GHK-Cu has been FDA approved.
FDA COMPOUNDING HISTORY
Your Project profile documents a significant regulatory update.
Injectable GHK-Cu had previously appeared in FDA 503A Category 2.
On April 15, 2026, FDA confirmed removal of injectable GHK-Cu from Category 2 after the original nomination was withdrawn.
Your Project source specifically notes that this removal occurred without a formal FDA safety determination.
IMPORTANT REGULATORY DISTINCTION
Removal from Category 2 does not mean:
GHK-Cu became FDA approved
FDA determined injectable GHK-Cu is safe
FDA established injectable efficacy
All compounded GHK-Cu products became approved drugs
The Project profile notes that future FDA or Pharmacy Compounding Advisory Committee review could still affect its regulatory status.
SPORT & COMPETITION
Your Project source states that GHK-Cu is not currently identified as a specifically prohibited substance under WADA solely by name, while also advising athletes to verify current anti-doping rules and product composition.
IMPORTANT DISTINCTION
Cosmetic ingredient status ≠ drug approval
Removal from a compounding category ≠ FDA approval
Topical human evidence ≠ validation of injectable use
ANALYTICAL DOCUMENTATION
Croix maintains available third party analytical documentation only for specific samples and lots that can be matched to corresponding laboratory reports.
GHK-Cu 50 MG
Laboratory
Optiq Health Labs
Sample Name
ghk-cu 50mg
Lot
05282026-1
Sample ID
1269.OPT.260910
Report Date
September 18, 2026
Sample Matrix
Lyophilized Peptide
Intended Use
Research Use Only
Reported Net Content
51.27 mg/vial
Reported Purity
99.5%
Identity
LC-MS Confirmation • GHK-Cu Tested
Endotoxin
Pass • LAL ≤ 0.05 EU/mg
Sterility
Pass • USP <71> • No Growth COAs-2(2)
IMPORTANT COA LIMITATION
Analytical results apply only to the specific sample identified in the corresponding laboratory report.
A Certificate of Analysis for one sample does not establish the composition, purity, sterility, safety, efficacy, or characteristics of another sample, lot, batch, or product.
The laboratory specifically states that the certificate is limited to the sample received and tested and does not represent or warrant the quality, composition, or characteristics of another sample, lot, batch, product, or material. COAs-2(2)
Croix requires the product, strength, lot or batch, sample ID, laboratory, and report date to be matched before analytical documentation is represented as supporting a product.
A passing COA does not establish FDA approval, clinical efficacy, medical suitability, or the characteristics of unrelated lots.
SELECTED RESEARCH & REFERENCES
Pickart L, Margolina A.
A Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data.
International Journal of Molecular Sciences. 2018.
Review examining GHK-Cu, gene expression, tissue remodeling, and regenerative biology.
Pickart L, Vasquez-Soltero JM, Margolina A.
GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration.
BioMed Research International. 2015.
Review of GHK-Cu signaling and skin-regeneration pathways.
Pickart L, Vasquez-Soltero JM, Margolina A.
The Human Tripeptide GHK-Cu in Prevention of Oxidative Stress and Degenerative Conditions of Aging.
Oxidative Medicine and Cellular Longevity. 2012.
Research review concerning GHK-Cu and oxidative-stress biology.
Pickart L, Margolina A.
GHK-Cu may Prevent Oxidative Stress in Skin by Regulating Copper and Modifying Expression of Numerous Antioxidant Genes.
Cosmetics. 2015.
Mechanistic gene-expression and antioxidant research.
Leyden J, Stephens T, Finkey M, Appa Y, Barkovic S.
Human facial-cream research involving copper peptide GHK-Cu.
Human topical cosmetic evidence involving approximately 12 weeks of use.
Vavra Research Inc.
IRB-approved human study evaluating stabilized GHK-Cu topical gel and skin collagen density.
Recent pilot-level topical human evidence.
Pickart L.
The human tri-peptide GHK and tissue remodeling.
Review of preclinical wound-healing and tissue-remodeling evidence.
U.S. Food & Drug Administration
503A Bulks List and 2026 regulatory materials concerning injectable GHK-Cu.
EVIDENCE NOTE
GHK-Cu has a route-dependent evidence base.
The strongest human evidence concerns topical cosmetic applications, particularly skin remodeling and collagen-related outcomes.
Systemic injectable GHK-Cu has not been validated through comparable randomized human trials.
Topical outcomes should therefore not be represented as established injectable benefits.
RESEARCH & EDUCATIONAL INFORMATION
This profile is provided for research and educational reference. It does not constitute individualized medical advice or establish injectable GHK-Cu as safe or effective for personal use.
GHK-Cu is a naturally occurring copper-binding peptide with meaningful research involving skin biology, extracellular-matrix remodeling, collagen, wound repair, gene expression, and related cellular pathways.
Human evidence is strongest for topical skin applications.
Injectable GHK-Cu is not an FDA-approved therapeutic drug, and comparable randomized human evidence establishing systemic cosmetic, hair, wound-healing, or regenerative benefits is lacking.
Cosmetic ingredient use, mechanistic research, animal findings, and topical clinical evidence should not be interpreted as establishing the safety or efficacy of injectable GHK-Cu.
Analytical documentation presented by Croix applies only to the specific samples and lots identified in corresponding laboratory reports.